Bill Gates and the Pan American Health Organization (PAHO) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S’ (NYSE:NVO) Wegovy and Eli Lilly and Co.’s (NYSE:LLY) Mounjaro in low- and middle-income countries.
The initiative aims to reduce the global inequality in obesity treatment, which remains a major health and economic burden worldwide.
